Agents and Actions

, Volume 30, Issue 1–2, pp 161–165 | Cite as

Cytochrome P-450 metabolic-intermediate complex formation with a series of diphenhydramine analogues

  • A. Bast
  • A. J. Valk
  • H. Timmerman
Histamine Receptors and Antihistamines

Abstract

A series of diphenhydramine analogues have been studied with regard to their formation of a metabolic intermediate (MI) during their biotransformation in phenobarbital induced rat hepatic microsomes. The MI forms a complex with reduced cytochrome P-450. MI complexation of cytochrome P-450 may result in drug-drug interactions and/or in cumulation of the parent compound. The extent of MI complex formation could be correlated with the lipophilicity of the substrates in a parabolic manner. A hydrophobic pocket of limited dimensions in cytochrome P-450 for the N-alkyl substituent of the substrates can be assumed. Moreover our data indicate a role for the O-atom in the diphenhydramine analogues for the interaction with cytochrome P-450.

Keywords

Complex Formation Phenobarbital Parent Compound Diphenhydramine Hydrophobic Pocket 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    M. R. Franklin,Inhibition of mixed-function oxidations by substrates forming reduced cytochrome P-450 metabolic-intermediate complexes. Pharmacol. Ther. Part A3, 227–245 (1977).Google Scholar
  2. [2]
    A. Bast, E. M. Savenije-Chapel and J. Noordhoek,Relationship between molecular structure and cytochrome P-450-metabolic intermediate complex formation. J. Pharm. Sci.73, 953–956 (1984).PubMedGoogle Scholar
  3. [3]
    U. B. Paulsen-Sörman, K.-H. Jönssen and B. G. A. Lindeke,Cytochrome P-455 nm complex formation in the metabolism of phenylalkylamines 8. Stereoselectivity in metabolic intermediary complex formation with a series of chiral 2-substituted 1-phenyl-2-aminoethanes. J. Med. Chem.27, 342–346 (1984).PubMedGoogle Scholar
  4. [4]
    A. Bast and J. Noordhoek,Spectral interactions of orphenadrine and its metabolites with oxidized and reduced hepatic microsomal cytochrome P-450 in the rat. Biochem. Pharmacol.31, 2745–2753 (1982).PubMedGoogle Scholar
  5. [5]
    A. Bast, E. M. Savenije-Chapel, F. A. A. van Kemenade, L. W. C. Scheefhals and J. Noordhoek,Effect of multiple administration of orphenadrine or mono-N-desmethylorphenadrine on cytochrome P-450 catalyzed reactions in the rat. Arch. Toxicol.54, 131–137 (1983).PubMedGoogle Scholar
  6. [6]
    M. Hirata, B. Lindeke and S. Orrenius,Cytochrome P-450 product complexes and glutathione consumption produced in isolated hepatocytes by norbenzphetamine and its N-oxidized congeners. Biochem. Pharmacol.28, 479–484 (1979).PubMedGoogle Scholar
  7. [7]
    D. Larrey, M. Tinel, P. Letteron, J. Geneve, V. Descatoire and D. Pessayre,Formation of an inactive cytochrome P-450Fe(II)-metabolite complex after administration of amiodarone in rats, mice and hamsters. Biochem. Pharmacol.35, 2213–2220 (1986).PubMedGoogle Scholar
  8. [8]
    A. Bast, F. A. A. van Kemenade, E. M. Savenije-Chapel and J. Noordhoek,Product inhibition in orphenadrine metabolism as a result of a stable cytochrome P-450-metabolic intermediate complex formed during the disposition of mono-N-desmethylorphenadrine (tofenacine) in the rat. Res. Commun. Chem. Pathol. Pharmacol.40, 391–403 (1983).PubMedGoogle Scholar
  9. [9]
    R. F. Rekker and H. M. de Kort,The hydrophobic fragmental constant; an extension to a 1000 data point set. Eur. J. Med. Chem.14, 479–488 (1979).Google Scholar
  10. [10]
    L. K. Pershing and M. R. Frankling,Cytochrome P-450 metabolic-intermediate complex formation and induction by macrolide antibiotics; a new class of agents. Xenobiotica12, 687–699 (1982).PubMedGoogle Scholar
  11. [11]
    M. R. Franklin, C. R. Wolf, C. Serabjit-Singh, R. M. Philpot,Quantitation of two forms of pulmonary cytochrome P-450 in microsomes, using substrate specificities. Mol. Pharmacol.17, 415–420 (1980).PubMedGoogle Scholar
  12. [12]
    C. Hansch,quantitative relationships between lipophilic character and drug metabolism. Drug Metab. Rev.1, 1–13 (1972).Google Scholar
  13. [13]
    D. Larrey, M. Tinel and D. Pessayre,Formation of inactive cytochrome P-450Fe(II) metabolic complexes with several erythromycin derivatives but not with josamycin and midecamycin in rats. Biochem. Pharmacol.32, 1487–1493 (1983).PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1990

Authors and Affiliations

  • A. Bast
    • 1
  • A. J. Valk
    • 1
  • H. Timmerman
    • 1
  1. 1.Department of Pharmacochemistry, Faculty of ChemistryVrije UniversiteitAmsterdamThe Netherlands

Personalised recommendations